Speculation regarding poorer outcomes for those with high cholesterol and/or heart disease infected with SARS-CoV-2 are well known. A real-world study published by the FH Foundation confirms Covid-19 increased heart attack rates significantly in patients with these conditions.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.
Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).
People who do not consistently get the same amount of sleep or go to bed at the same time each night may be more likely to develop health problems like obesity, high blood pressure, high cholesterol and diabetes, a recent study suggests.
Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.
People who have recently experienced a stroke may be more than twice as likely to develop dementia than individuals who have not had a stroke, a new study suggests.
Alnylam Pharmaceuticals’ Onpattro won U.S. regulatory approval for a rare hereditary disease, becoming the first approved treatment from a new class of medicines that use gene silencing technology.
AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.